Tuam Tshoj Venetoclax 1257044-40-8 manufacturers thiab lwm |CPF

Venetoclax 1257044-40-8

Lus piav qhia luv luv:

API lub npe	Qhov taw qhia	Innovator	Patent Expiry Date (Tebchaws Asmeskas)
Venetoclax 1257044-40-8	CLL	Abbvie	Lub Rau Hli 27, 2031

Xa email rau peb

Product Detail

Khoom cim npe

KHOOM PLIG

维奈妥拉	Venetoclax	1257044-40-8	Hauv tsev
VCL-6A		98549-88-3	Hauv tsev
VCL-7A		1235865-75-4	Hauv tsev
VWM 2		1228780-72-0	Hauv tsev
VCLM2-2 HCL		1628047-87-9	Hauv tsev
VWM 3		1228779-96-1	Hauv tsev

GLub npe eneric:venetoclax (ven ET oh klax)
Hom Lub Npe: Venclexta, Venclexta Pib Pob

Venetoclax yog siv los kho tus mob lymphocytic leukemia los yog lymphocytic leukemia me me rau cov neeg laus.Venetoclax yog siv ib leeg lossis ua ke nrog lwm cov tshuaj kho mob qog noj ntshav los kho cov mob no.

Venetoclax yog siv ua ke nrog azacitidine, decitabine, los yog cytarabine los kho mob myeloid leukemia.Qhov kev sib xyaw ua ke no yog siv rau cov neeg laus uas muaj hnub nyoog 75 xyoos lossis tshaj saud, lossis cov uas tsis tuaj yeem siv cov tshuaj khomob vim muaj lwm yam mob.

Venetoclax qee zaum tau muab tom qab lwm yam kev kho mob ua tsis tiav.

Venetoclax kuj tseem siv tau rau cov hom phiaj tsis tau teev tseg hauv phau ntawv qhia tshuaj no.

Kev piav qhia

Venetoclax (ABT-199; GDC-0199) yog ib qho muaj zog, xaiv thiab hais lus bioavailable Bcl-2 inhibitor nrog Ki ntawm tsawg dua 0.01 nM.Venetoclax induces autophagy.

Hauv Vitro

Venetoclax (ABT-199) muaj peev xwm tua FL5.12-BCL-2 hlwb (EC50 = 4 nM), Venetoclax (ABT-199) qhia ntau yam tsis muaj zog tiv thaiv FL5.12-BCL-XL hlwb (EC50 = 261 nM).ABT-199 kuj qhia txog kev xaiv hauv cellular mammalian ob-hybrid kev soj ntsuam, qhov twg nws cuam tshuam BCL-2-BIM complexes (EC50 = 3 nM) tab sis tsis tshua muaj txiaj ntsig rau BCL-XL-BCL-XS (EC50 = 2.2).μM) los yog MCL-1-NOXA complexes.

Tom qab ib koob tshuaj ntawm ib qhov ncauj ntawm 12.5 mg ib kg lub cev qhov hnyav hauv xenografts muab los ntawm RS4; 11 hlwb (TAG NRHO), Venetoclax (ABT-199) ua rau cov qog loj tshaj plaws inhibition (TGImax) ntawm 47% (P<0.001) thiab cov qog loj hlob. ncua (TGD) ntawm 26% (P<0.05)[1].

Kev kho mob ntawm xenografted (tus qauv nas xenograft ntawm T-ALL cell kab LOUCY) cov qog nrog Venetoclax (ABT-199) 100 mg / kg rau 4 hnub ua rau txo qis ntawm leukemic lub nra.

Cia